Plasmatic parameters of coagulation activation in thrombotic microangiopathy

Biomedicine and Pharmacotherapy

Volumn 50, Issue 8, 1996, Pages 357-362

  Sagripanti, A ^a,c   Carpi, A ^a   Baicchi, U ^a   Morganti, M ^b   Rosaia, B ^a   Nicolini, A ^a   Mittermayer, C ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Coagulation; D dimer; Fibrinolysis; Thrombin antithrombin III complex; Thrombotic microangiopathy

Indexed keywords

ANTITHROMBIN III; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; BLOOD CLOTTING; CLINICAL ARTICLE; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0029828421     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(96)89668-5     Document Type: Conference Paper

References (18)

1. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: reports of 16 cases and review of the literature. Medicine 1965;45:139-59
2. Asada Y, Sumiyoshi A, Hayashi T, Suzumiha J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985;38:469-79
3. Bauer KA, Rosenberg RD. The pathophysiology of the pre-thrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987;70:343-50
4. Bell WR, Braine HG, Ness PM, Kikler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403
5. George JN, El-Harake ME. Thrombocytopenia due to enhanced platelet destruction by non immunologic mechanism. In: Beutler E, Lichtmann MA, Collec BS, Kipps TJ, eds. Williams Hematology, 5th edn. New York: McGraw Hill, 1995;1290-315
6. Glas-Greenwait P, Hall JM, Panke TW, Kant KS, Allen CM, Pollak VER. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor and protein C in thrombotic thrombocytopenic purpura. J Lab Clin Med 1986;108:415-22
7. Jaffe EA, Nachman RL, Merskey C. Thrombotic thrombocytopenic purpura: coagulation parameters in twelve patients. Blood 1973;42:499-507
8. Kahishita E, Koyama T, Higuchi M, Kunitomi O, Oura Y, Nagai K. Fibrinogenolysis in thrombotic thrombocytopenic purpura. Am J Hematol 1989;32:14-9
9. Kwaan HC. Role of fibrinolysis in thrombotic thrombocytopenic purpura. Semin Hematol 1978;24:101-09
10. Lau DH, Wum T. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med 1993;95:544-45
11. Monteagudo J, Pereira A, Reverter JC et al. Thrombin generation and fibrinolysis in the thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Thromb Haemostas 1991;66:515-19
12. Pelzer H, Schawarz A, Stuber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a syntethic peptide. Thromb Haemostas 1991;65:153-59
13. Remuzzi G, Mecca G, Livio M et al. Prostacyclin generation by cultured endothelial cells in hemolytic-uremic syndrome. Lancet 1980;I:656-57
14. Remuzzi G, Ruggenenti P. The hemolytic-uremic syndrome. Kidney Int 1995;47:2-19
15. Rylatt DB, Blake AS, Cottis LE et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767-68
16. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991;325:393-97
17. Rose M, Eldor A. High incidence of relapse in thrombotic thrombocytopenic purpura. Am J Med 1987;83:437-44
18. Takahashi H, Takakuwa E, Yoshino N, Hanano M, Shibata A. Protein C levels in disseminated intravascular coagulation and thrombotic thrombocytopenic purpura: its correlation with other coagulation. Blood 1983;54:445-59